Compare BATRA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BATRA | BEAM |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | BATRA | BEAM |
|---|---|---|
| Price | $42.35 | $28.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $58.00 | $48.09 |
| AVG Volume (30 Days) | 52.1K | ★ 1.4M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,307,000.00 | $55,701,000.00 |
| Revenue This Year | $12.40 | N/A |
| Revenue Next Year | $6.78 | $26.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.62 | N/A |
| 52 Week Low | $38.67 | $13.53 |
| 52 Week High | $50.50 | $35.25 |
| Indicator | BATRA | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 60.35 |
| Support Level | $42.30 | $26.25 |
| Resistance Level | $44.05 | $28.00 |
| Average True Range (ATR) | 0.71 | 1.44 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 17.03 | 55.94 |
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.